Hereditary Transthyretin Amyloidosis (hATTR) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Alnylam, Ionis, Novo Nordisk

Hereditary Transthyretin Amyloidosis (hATTR) Pipeline Analysis (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Alnylam, Ionis, Novo Nordisk
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 8+ key pharma and biotech companies are working on 8+ pipeline drugs in the Hereditary Transthyretin Amyloidosis (hATTR) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Hereditary Transthyretin Amyloidosis (hATTR) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Hereditary Transthyretin Amyloidosis Market. 

The Hereditary Transthyretin Amyloidosis Pipeline report embraces in-depth commercial, regulatory, and Hereditary Transthyretin Amyloidosis clinical trial assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the emerging Hereditary Transthyretin Amyloidosis drugs, including the mechanism of action, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Hereditary Transthyretin Amyloidosis (hATTR) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for Hereditary Transthyretin Amyloidosis treatment and the aggregate therapies developed by major pharma companies.

  • It accesses the different Hereditary Transthyretin Amyloidosis therapies segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the major Hereditary Transthyretin Amyloidosis companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the Hereditary Transthyretin Amyloidosis drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Hereditary Transthyretin Amyloidosis therapeutic market.

Hereditary Transthyretin Amyloidosis (hATTR) Therapeutics Landscape

Since TTR protein is mainly produced in the liver, transplanting a new liver should almost eliminate the production of variant protein and further halt the disease progression outside the brain and eyes. Orthotopic liver transplant (OLT) is an established option for patients with early-stage disease; however, it might not eliminate the progression of the disease, because TTR produced by the transplanted liver can accumulate on the preexisting deposits. The other limitations of OLT include limited organ availability, surgical morbidity, and mortality, the need for lifelong immunosuppression, and the high cost of liver transplantation.

Recently few drugs have been approved for the treatment of hATTR. The approved therapies include inotersen (Tegsedi), patisiran (Onpattro), tafamidis meglumine (Vyndaqel), and tafamidis (Vyndamax).

To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Hereditary Transthyretin Amyloidosis (hATTR). Currently, Alnylam Pharmaceuticals is leading the therapeutics market with its Hereditary Transthyretin Amyloidosis (hATTR) drug candidates in the most advanced stage of clinical development.

Hereditary Transthyretin Amyloidosis (hATTR) Companies Actively Working in the Therapeutic Market Include:

  • Alnylam Pharmaceuticals

  • Ionis Pharmaceuticals

  • Eidos Therapeutics

  • Intellia Therapeutics

  • Corino Therapeutics

  • Novo Nordisk

And Many Others

Emerging and Marketed Hereditary Transthyretin Amyloidosis (hATTR) Drugs Covered in the Report Include:

  • Vutrisiran: Alnylam Pharmaceuticals

  • AKCEA-TTR-LRx: Ionis Pharmaceuticals

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Hereditary Transthyretin Amyloidosis Companies Working in the Market @

Analysis of Emerging Hereditary Transthyretin Amyloidosis Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued and inactive candidates

Route of Administration

Hereditary Transthyretin Amyloidosis (hATTR) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral

  • Parenteral

  • Intravenous

  • Subcutaneous

  • Topical

Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody

  • Peptides

  • Polymer

  • Small molecule

  • Gene therapy

Learn How the Hereditary Transthyretin Amyloidosis Treatment Outlook will Evolve with the Ongoing Clinical and commercial Activities in the Therapeutic Market @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Hereditary Transthyretin Amyloidosis Treatment Patterns

4. Hereditary Transthyretin Amyloidosis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Hereditary Transthyretin Amyloidosis Late Stage Products (Phase-III)

7. Hereditary Transthyretin Amyloidosis Mid-Stage Products (Phase-II)

8. Hereditary Transthyretin Amyloidosis Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Hereditary Transthyretin Amyloidosis Discontinued Products

13. Hereditary Transthyretin Amyloidosis Product Profiles

14. Major Hereditary Transthyretin Amyloidosis Companies in the Market

15. Key Products in the Hereditary Transthyretin Amyloidosis Therapeutics Segment

16. Dormant and Discontinued Products

17. Hereditary Transthyretin Amyloidosis Unmet Needs

18. Hereditary Transthyretin Amyloidosis Future Perspectives

19. Hereditary Transthyretin Amyloidosis Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Migraine Market

“Migraine Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Migraine market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Migraine market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States